Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Ashleigh KussmanDavid ShyrGregory HaleBenjamin R OshrineAleksandra PetrovicPublished in: Pediatric blood & cancer (2018)
Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy-induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine- or high-dose cytarabine-based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced-intensity conditioning and allogeneic transplant before hematologic recovery. Long-term disease control was achieved in five, with one transplant-related mortality, suggesting the feasibility of this approach.
Keyphrases
- acute myeloid leukemia
- chemotherapy induced
- high dose
- stem cell transplantation
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- young adults
- end stage renal disease
- newly diagnosed
- prognostic factors
- low dose
- stem cells
- rheumatoid arthritis
- cardiovascular disease
- systemic lupus erythematosus
- risk factors
- high intensity
- immune response
- disease activity
- locally advanced
- free survival
- acute lymphoblastic leukemia